Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% – Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was up 4.6% during trading on Friday . The stock traded as high as $6.20 and last traded at $6.22. Approximately 4,144,273 shares changed hands during trading, a decline of 60% from the average daily volume of 10,307,810 shares. The stock had previously closed at $5.94.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several recent analyst reports. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Stock Up 6.6 %

The firm has a market capitalization of $2.55 billion, a PE ratio of -4.15 and a beta of 0.85. The stock has a 50-day simple moving average of $7.57 and a 200-day simple moving average of $7.03. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter in the previous year, the business earned ($0.42) EPS. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% on a year-over-year basis. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Integrated Advisors Network LLC lifted its holdings in Recursion Pharmaceuticals by 36.8% during the 4th quarter. Integrated Advisors Network LLC now owns 17,588 shares of the company’s stock worth $119,000 after purchasing an additional 4,731 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at $54,000. CSS LLC IL purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Recursion Pharmaceuticals by 5.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company’s stock worth $15,272,000 after purchasing an additional 118,428 shares during the period. Finally, Vident Advisory LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $80,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.